U.S. Stocks Movement: Celcuity surged on September 30 due to REVTORPYK listing and breast cancer drug news
Bitget异动解读2026/09/30 13:35Celcuity September 30 Interpretation of Surge
Keywords: REVTORPYK launch, breast cancer drug
1. On September 30, 2026, Celcuity announced that REVTORPYK (Gedatolisib) has been commercially launched in the United States. It is suitable for patients with HR+/HER2- locally advanced or metastatic breast cancer who have progressed after at least one line of endocrine therapy and who do not have a PIK3CA mutation detected. It can be used as a monotherapy with fulvestrant or in combination with pembrolizumab.
2. On September 30, 2026, the company disclosed that REVTORPYK is the first and only FDA-approved therapy that simultaneously inhibits all Class I PI3K isoenzymes and mTORC1/2. In the VIKTORIA-1 study PIK3CA wild-type cohort, the triple and double regimens reduced the risk of disease progression or death by 76% and 67%, respectively, compared to fulvestrant.
(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Rocket Lab signs 20-launch contract with Synspective, rises nearly 3% after hours
Kashkari says the labor market is quite good with no signs of deterioration.
